Kornhuber J, Brücke T, Angelberger P, Asenbaum S, Podreka I
University Clinics for Neurology and Nuclear Medicine, Vienna, Austria.
J Neural Transm Gen Sect. 1995;101(1-3):95-103. doi: 10.1007/BF01271548.
[123I]Epidepride is a new ligand for single photon emission computerized tomography (SPECT) that specifically labels D2-like dopamine receptors with very high affinity. Here, we report on the regional kinetic uptake of [123I]epidepride in the brain of 4 normal volunteers and 3 patients with choreatic movement disorders. In healthy subjects striatal activity peaked at 2.5 hours after injection of the tracer and decreased slowly thereafter. There were no significant differences between left and right brain hemispheres. Activity above background was also measurable in areas corresponding to the thalamus, temporal cortex and frontal cortex. The striatal to cerebellar ratio was about 14 after 2.5 hours and this ratio steadily increased with time. The striatal to cerebellar ratio was clearly reduced in all 3 patients with choreatic movement disorders (from about 14 in control subjects after 2.5 hours to about 7 in choreatic patients). [123I]Epidepride may be a useful SPECT ligand for studying D2 receptors in the living human brain because of its high target to background ratio, its high affinity and the possibility to investigate extrastriatal D2 receptors.
[123I]表哌立得是一种用于单光子发射计算机断层扫描(SPECT)的新型配体,它能以非常高的亲和力特异性标记D2样多巴胺受体。在此,我们报告了[123I]表哌立得在4名正常志愿者和3名患有舞蹈样运动障碍患者大脑中的区域动力学摄取情况。在健康受试者中,纹状体活性在注射示踪剂后2.5小时达到峰值,此后缓慢下降。左右脑半球之间无显著差异。在与丘脑、颞叶皮质和额叶皮质相对应的区域也可测量到高于背景的活性。2.5小时后纹状体与小脑的比值约为14,且该比值随时间稳步增加。在所有3名患有舞蹈样运动障碍的患者中,纹状体与小脑的比值明显降低(从2.5小时后对照受试者的约14降至舞蹈样患者的约7)。由于[123I]表哌立得具有高靶本底比值、高亲和力以及研究纹状体以外D2受体的可能性,它可能是一种用于在活体人脑中研究D2受体的有用SPECT配体。